Agreements reached under this partnership
Capital and Business Alliance- 1
Transformation of the domestic general health checkup business model: We will promote a transformation of the business model from a conventional provider of annual health checkups into a company that supports corporate health management.
- 2
Overseas expansion of the product business: We will expand supplements, including plasmalogen, equol and NMN, as well as cosmetics, overseas by leveraging distribution networks in Japan and abroad.
- 3
Opening of new facilities for regenerative medicine projects: We aim to expand our service offerings by opening new facilities for AMC’s regenerative medicine projects, including the Nakanoshima Regenerative Medicine Center and Ginza Clinic.
- 4
Overseas expansion of advanced medical and health checkup centers: In cooperation with leading local partners, we will expand advanced medical facilities offering cutting-edge treatments, medical screening, preventive medicine and other services into ASEAN countries, the Middle East and other regions.
- 5
Expansion of the inbound business: We will strengthen the provision of regenerative medicine, longevity medicine and other high-value-added Japanese medical services to overseas customers, primarily from ASEAN countries and China.
- 6
Strengthening of the management structure: Through personnel exchanges with Mitsubishi Corporation, we will jointly promote reforms in AMC’s corporate planning, overseas expansion and corporate health checkup business.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Target of achieving medical business operating profit of ¥20 billion in fiscal 2034
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
| Item | Details |
|---|---|
| Name of alliance partner | Mitsubishi Corporation |
| Alliance partner's business activities | Mitsubishi Corporation operates diversified businesses across a broad range of industries through seven groups: Energy & Power Solution, Materials Solution, Mineral Resources, Social Infrastructure, Mobility, Food Industry, and S.L.C. (Smart-Life Creation). |
| Alliance partner's location | Chiyoda-ku, Tokyo |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Transformation of the domestic general health checkup business model: We will promote a transformation of the business model from a conventional provider of annual health checkups into a company that supports corporate health management., Overseas expansion of the product business: We will expand supplements, including plasmalogen, equol and NMN, as well as cosmetics, overseas by leveraging distribution networks in Japan and abroad., Opening of new facilities for regenerative medicine projects: We aim to expand our service offerings by opening new facilities for AMC’s regenerative medicine projects, including the Nakanoshima Regenerative Medicine Center and Ginza Clinic., Overseas expansion of advanced medical and health checkup centers: In cooperation with leading local partners, we will expand advanced medical facilities offering cutting-edge treatments, medical screening, preventive medicine and other services into ASEAN countries, the Middle East and other regions., Expansion of the inbound business: We will strengthen the provision of regenerative medicine, longevity medicine and other high-value-added Japanese medical services to overseas customers, primarily from ASEAN countries and China., Strengthening of the management structure: Through personnel exchanges with Mitsubishi Corporation, we will jointly promote reforms in AMC’s corporate planning, overseas expansion and corporate health checkup business. |
| Dispatch of directors and officers | Through personnel exchanges with Mitsubishi Corporation, we will jointly promote reforms in AMC’s corporate planning, overseas expansion and corporate health checkup business. Dispatch of directors and audit & supervisory board members: Not disclosed |
| Numerical targets under the alliance | Target of achieving medical business operating profit of ¥20 billion in fiscal 2034 |
| Contract Date | 12 August 2026 |
| Share Acquisition Date and Payment Date | 1 October 2026 (scheduled) |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The alliance will combine Mitsubishi Corporation’s global network and knowledge across a diverse range of industries with AMC’s expertise in preventive medicine and wellness, with the aim of accelerating the overseas expansion of the medical business and transforming the business model of existing domestic operations.